Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytomX TherapeuticsCTMX +2.96%38 3-Year EPS without NRI Growth Rate is 53.70% as of Jun. 2026, which is 1313% above its 10-year median of 3.80. GuruFocus rates CTMX with a GF Score™ of 38/100 and a GF Value™ of $0.14 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,160 Biotechnology companies, CytomX Therapeutics ranks better than 87.07% on this metric.
During the past 12 months, CytomX Therapeutics's average EPS without NRI Growth Rate was -187.70% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 53.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of CytomX Therapeutics was 80.70% per year. The lowest was -55.40% per year. And the median was 3.80% per year.
CytomX Therapeutics (NAS:CTMX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
CytomX Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
CTMX vs GYRE, BBOT, TECX: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, CytomX Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytomX Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where CytomX Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
CytomX Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 53.70% mean?
CytomX Therapeutics (CTMX) has a 3-Year EPS without NRI Growth Rate of 53.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for CytomX Therapeutics and its competitors. This is 1313% above median its historical median of 3.80. According to the industry distribution chart, CytomX Therapeutics ranks #150 out of 1160 companies in the Biotechnology industry, placing it in the top 12.9%.
Is CytomX Therapeutics' 3-Year EPS without NRI Growth Rate too high?
CytomX Therapeutics' current 3-Year EPS without NRI Growth Rate of 53.70% is 1313% above median its 10-year median of 3.80. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. CytomX Therapeutics' value of 53.70% is 231.5% above this industry median. Based on the distribution chart, CytomX Therapeutics ranks #150 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CytomX Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' 3-Year EPS without NRI Growth Rate compare to GYRE and BBOT?
According to the Biotechnology industry distribution chart, CytomX Therapeutics ranks #150 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places CytomX Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.20. CytomX Therapeutics' value of 53.70% is 231.5% above this benchmark. While the company's 10-year median is 3.80 vs. the industry median of 16.20, CytomX Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytomX Therapeutics's current 3-Year EPS without NRI Growth Rate of 53.70% is 231.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for CytomX Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytomX Therapeutics's current 3-Year EPS without NRI Growth Rate is 53.70%, which is 1313% above median its own 10-year median of 3.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.14, compared to a current price of $3.31 — trading 2260.7% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 53.70%, which is 1313% above median its 10-year median of 3.80 and 231.5% above the Biotechnology industry median of 16.20. CytomX Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current 3-Year EPS without NRI Growth Rate is 53.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytomX Therapeutics (CTMX) Overvalued in 2026?
Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued.
The current stock price of $3.31 is trading 2260.7% above its estimated GF Value™ of $0.14.
GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.
Key valuation signals for CTMX:
3-Year EPS without NRI Growth Rate: 53.70% (1313% above median its 10-year median of 3.80)
GF Value™: $0.14 vs. price of $3.31 (2260.7% above fair value)
Industry Position: 231.5% above the Biotechnology median (#150 of 1160)
No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
38GF Score
Get the complete analysis for CTMX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTMX has been successfully added to your 
